Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Cost of Revenue (2016 - 2025)

Teva Pharmaceutical Industries (TEVJF) has disclosed Cost of Revenue for 10 consecutive years, with -$766.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 15.55% year-over-year to -$766.0 million, compared with a TTM value of $2.7 billion through Dec 2025, up 5.71%, and an annual FY2025 reading of $2.7 billion, up 5.71% over the prior year.
  • Cost of Revenue was -$766.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $2.2 billion in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.2 billion in Q3 2024 and bottomed at -$3.8 billion in Q4 2023.
  • Average Cost of Revenue over 5 years is $896.4 million, with a median of $1.3 billion recorded in 2022.
  • The sharpest move saw Cost of Revenue tumbled 280.93% in 2023, then skyrocketed 278.99% in 2024.
  • Year by year, Cost of Revenue stood at $2.1 billion in 2021, then grew by 3.07% to $2.1 billion in 2022, then crashed by 280.93% to -$3.8 billion in 2023, then soared by 76.28% to -$907.0 million in 2024, then grew by 15.55% to -$766.0 million in 2025.
  • Business Quant data shows Cost of Revenue for TEVJF at -$766.0 million in Q4 2025, $2.2 billion in Q3 2025, and -$738.0 million in Q2 2025.